insights

Insights

Explore our thought leadership insights,
as life science technologies evolve and accelerate.

All Insights
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
DeciBio Q&A
The Broadening Use of siRNA in the Clinic: DeciBio's Q&A with June Park, CEO of siRNAgen Therapeutics
Read our lastest Q&A with June Park, CEO of siRNAgen, a novel RNAi platform spun out of Korea-based Bioneer
November 21, 2022
DeciBio Q&A
The Broadening Use of siRNA in the Clinic: DeciBio's Q&A with June Park, CEO of siRNAgen Therapeutics
Read our lastest Q&A with June Park, CEO of siRNAgen, a novel RNAi platform spun out of Korea-based Bioneer
November 21, 2022
DeciBio Q&A
AI’s Impact on the Clinical Pathology Lab : DeciBio's Q&A with Paige’s CEO Andy Moye
Check out our latest Q&A with Andy Moye of Paige, a company using a cloud-based AI Platform to help drive drug discovery and treatment for cancer.
November 9, 2022
DeciBio Q&A
AI’s Impact on the Clinical Pathology Lab : DeciBio's Q&A with Paige’s CEO Andy Moye
Check out our latest Q&A with Andy Moye of Paige, a company using a cloud-based AI Platform to help drive drug discovery and treatment for cancer.
November 9, 2022
Newsletter Update
Liquid Biopsy | October Roundup
October brought numerous updates in the regulatory world for Liquid Biopsy (LBx), with additional developments in partnerships, clinical findings, and fundraising. 
November 8, 2022
Newsletter Update
Liquid Biopsy | October Roundup
October brought numerous updates in the regulatory world for Liquid Biopsy (LBx), with additional developments in partnerships, clinical findings, and fundraising. 
November 8, 2022
DeciBio Q&A
Automated Digital Health Intervention: DeciBio’s Q&A with Dr. Yossi Bahagon of Sweetch
In our latest Q&A, our experts spoke with Dr. Yossi Bahagon of Sweetch, an AI digital health platform.
November 4, 2022
DeciBio Q&A
Automated Digital Health Intervention: DeciBio’s Q&A with Dr. Yossi Bahagon of Sweetch
In our latest Q&A, our experts spoke with Dr. Yossi Bahagon of Sweetch, an AI digital health platform.
November 4, 2022
Newsletter Update
Next-Generation Therapeutics | October Roundup
Check out our newsletter to heard about the numerous exciting updates ranging from new company creation (Pheon Therapeutics) to major partnerships.
November 2, 2022
Newsletter Update
Next-Generation Therapeutics | October Roundup
Check out our newsletter to heard about the numerous exciting updates ranging from new company creation (Pheon Therapeutics) to major partnerships.
November 2, 2022
Blog Article
Pathology Visions 2022 - DeciBio Highlights: Growing Traction for Digital Pathology
Our experts highlight some of the key Digital Pathology trends and themes from the 2022 Pathology Visions conference.
October 31, 2022
Blog Article
Pathology Visions 2022 - DeciBio Highlights: Growing Traction for Digital Pathology
Our experts highlight some of the key Digital Pathology trends and themes from the 2022 Pathology Visions conference.
October 31, 2022
DeciBio Q&A
10x Genomics’ 2022 Spatial Biology Symposium Review: The New Xenium, Visium and Chromium Study Trifecta with Michael Schnall-Levin, CTO
Check out our latest Q&A with Michael Schnall-Levin, the Chief Technology Officer of 10x Genomics.
October 27, 2022
DeciBio Q&A
10x Genomics’ 2022 Spatial Biology Symposium Review: The New Xenium, Visium and Chromium Study Trifecta with Michael Schnall-Levin, CTO
Check out our latest Q&A with Michael Schnall-Levin, the Chief Technology Officer of 10x Genomics.
October 27, 2022
DeciBio Q&A
Targeted autoimmune diseases: DeciBio's Q&A with Isaac Stoner of Octagon Therapeutics
DeciBio recently had the chance to interview Isaac Stoner of Octagon Therapeutics about their new novel targeting approaches for autoimmune diseases.
October 25, 2022
DeciBio Q&A
Targeted autoimmune diseases: DeciBio's Q&A with Isaac Stoner of Octagon Therapeutics
DeciBio recently had the chance to interview Isaac Stoner of Octagon Therapeutics about their new novel targeting approaches for autoimmune diseases.
October 25, 2022
DeciBio Q&A
Taking Spatial Toward the Clinic: DeciBio’s Q&A with Sandy Au of NeoGenomics
Our spatial biology experts discuss key drivers of spatial biology utilization across the research continuum. Hear the keys to getting spatial biology to the clinic from an expert spatial operator and thought leader.
October 25, 2022
DeciBio Q&A
Taking Spatial Toward the Clinic: DeciBio’s Q&A with Sandy Au of NeoGenomics
Our spatial biology experts discuss key drivers of spatial biology utilization across the research continuum. Hear the keys to getting spatial biology to the clinic from an expert spatial operator and thought leader.
October 25, 2022
Blog Article
New and Established Early Detection Companies Work to Solidify their Standings: This is a Race to Watch
Building off last year's blog, this year we recap updates in the early detection (EDx) landscape that focus on last year’s developments, identify emerging players and technologies, and highlight some geographical considerations.
October 24, 2022
Blog Article
New and Established Early Detection Companies Work to Solidify their Standings: This is a Race to Watch
Building off last year's blog, this year we recap updates in the early detection (EDx) landscape that focus on last year’s developments, identify emerging players and technologies, and highlight some geographical considerations.
October 24, 2022
DeciBio Q&A
Off-The-Shelf Cell Therapies: DeciBio's Q&A with Steve Kanner, Ph.D., CSO at Caribou Biosciences
Read as our experts interview with Steve Kanner, CSO at Caribou Biosciences.
October 20, 2022
DeciBio Q&A
Off-The-Shelf Cell Therapies: DeciBio's Q&A with Steve Kanner, Ph.D., CSO at Caribou Biosciences
Read as our experts interview with Steve Kanner, CSO at Caribou Biosciences.
October 20, 2022
DeciBio News
Worldwide Liquid Biopsy (LBx) Market Forecasted to Grow at 46% p.a., Reaching $8.6B by 2027 – Market Report by DeciBio Consulting LLC
DeciBio released a second edition liquid biopsy report that takes an updated and comprehensive look at the liquid biopsy (LBx) landscape.
October 19, 2022
DeciBio News
Worldwide Liquid Biopsy (LBx) Market Forecasted to Grow at 46% p.a., Reaching $8.6B by 2027 – Market Report by DeciBio Consulting LLC
DeciBio released a second edition liquid biopsy report that takes an updated and comprehensive look at the liquid biopsy (LBx) landscape.
October 19, 2022
In The Press
DeciBio Champions Data Solutions to Give Edge to Life Science Companies
Read our feature in the Los Angeles Business Journal, as it highlights the use of our data products to leverage the increasing entry fees needed by companies to compete in a precision medicine space.
October 17, 2022
In The Press
DeciBio Champions Data Solutions to Give Edge to Life Science Companies
Read our feature in the Los Angeles Business Journal, as it highlights the use of our data products to leverage the increasing entry fees needed by companies to compete in a precision medicine space.
October 17, 2022
In The Press
People, Pipelines, and Projections: What Can Be Done To Help Emerging Therapeutics Get to Market Efficiently?
IPT asked representatives from DeciBio, Cybin, and GORE PharmBIO for their opinions on how to help get therapeutics get to market more efficiently.
October 15, 2022
In The Press
People, Pipelines, and Projections: What Can Be Done To Help Emerging Therapeutics Get to Market Efficiently?
IPT asked representatives from DeciBio, Cybin, and GORE PharmBIO for their opinions on how to help get therapeutics get to market more efficiently.
October 15, 2022
Newsletter Update
Next-Generation Therapeutics | September Roundup
Read our September roundup to find out more about new key developments in the Next-Generation Therapeutics Space.
October 14, 2022
Newsletter Update
Next-Generation Therapeutics | September Roundup
Read our September roundup to find out more about new key developments in the Next-Generation Therapeutics Space.
October 14, 2022
DeciBio Q&A
DxBooks Insights: One reference lab's approach to the monkeypox outbreak
We sat down with a lab director to learn more about how a large reference lab approached monkeypox testing.
October 10, 2022
DeciBio Q&A
DxBooks Insights: One reference lab's approach to the monkeypox outbreak
We sat down with a lab director to learn more about how a large reference lab approached monkeypox testing.
October 10, 2022
Newsletter Update
Liquid Biopsy | September Roundup
Liquid Biopsy (LBx) continued to develop through September, featuring ample product launches and clinical trial publications spurred on by ESMO conferences. 
October 6, 2022
Newsletter Update
Liquid Biopsy | September Roundup
Liquid Biopsy (LBx) continued to develop through September, featuring ample product launches and clinical trial publications spurred on by ESMO conferences. 
October 6, 2022
Newsletter Update
Digital Health | Q3 Update
While the economic slump looks as though it may continue through the final quarter of 2022, we will continue to stay abreast of emerging developments in digital health.
October 5, 2022
Newsletter Update
Digital Health | Q3 Update
While the economic slump looks as though it may continue through the final quarter of 2022, we will continue to stay abreast of emerging developments in digital health.
October 5, 2022
Blog Article
IGF 2022: DeciBio Highlights – Illumina delivers
Read about our take on Illumina's new line of product launched at its inaugural Illumina Genomics Forum (IGF) last week.
October 3, 2022
Blog Article
IGF 2022: DeciBio Highlights – Illumina delivers
Read about our take on Illumina's new line of product launched at its inaugural Illumina Genomics Forum (IGF) last week.
October 3, 2022
DeciBio Q&A
Explainable, Unbiased AI and Computational Systems Pathology: Q&A with Dusty Majumdar and Chakra Chennubhotla of SpIntellx
DeciBio interviews Dusty Majumdar and Chakra Chennubhotla, CEO and CTO at SpIntellx.
September 22, 2022
DeciBio Q&A
Explainable, Unbiased AI and Computational Systems Pathology: Q&A with Dusty Majumdar and Chakra Chennubhotla of SpIntellx
DeciBio interviews Dusty Majumdar and Chakra Chennubhotla, CEO and CTO at SpIntellx.
September 22, 2022
DeciBio Q&A
Digital Pathology for Biomarker Development: Decibio’s Q&A with Chan-Young Ock of Lunit
Decibio interviews Dr. Chan-Young Ock of recently IPO’d digital pathology firm, Lunit.
September 21, 2022
DeciBio Q&A
Digital Pathology for Biomarker Development: Decibio’s Q&A with Chan-Young Ock of Lunit
Decibio interviews Dr. Chan-Young Ock of recently IPO’d digital pathology firm, Lunit.
September 21, 2022
Blog Article
Oncologist Perspectives on the Most Exciting Advancements in Precision Medicine
DeciBio conducted a pulse survey with 8 U.S. oncologists to ascertain what precision oncology advancements excite them the most.
September 21, 2022
Blog Article
Oncologist Perspectives on the Most Exciting Advancements in Precision Medicine
DeciBio conducted a pulse survey with 8 U.S. oncologists to ascertain what precision oncology advancements excite them the most.
September 21, 2022
In The Press
Mark a Course for the Future – Biomarkers in Cancer Immunotherapy
Here we explore how biomarkers are driving the immuno-oncology landscape. We dive into cutting-edge biomarker research and the challenges facing the field.
September 15, 2022
In The Press
Mark a Course for the Future – Biomarkers in Cancer Immunotherapy
Here we explore how biomarkers are driving the immuno-oncology landscape. We dive into cutting-edge biomarker research and the challenges facing the field.
September 15, 2022
Newsletter Update
Liquid Biopsy | August Roundup
Take a look at DeciBio’s in-depth recap of strategic liquid biopsy industry activity
September 6, 2022
Newsletter Update
Liquid Biopsy | August Roundup
Take a look at DeciBio’s in-depth recap of strategic liquid biopsy industry activity
September 6, 2022
Newsletter Update
Next-Generation Therapeutics | August Roundup
August was a month that had some significant new therapeutic approvals as well as company launches, in addition to several financing rounds and partnerships. Read below to find out more about these new key developments. 
September 1, 2022
Newsletter Update
Next-Generation Therapeutics | August Roundup
August was a month that had some significant new therapeutic approvals as well as company launches, in addition to several financing rounds and partnerships. Read below to find out more about these new key developments. 
September 1, 2022
Blog Article
Decibio Analytics launches inaugural NGS Oncology DxBook
Discover the new DxBook for clinical NGS oncology testing.
August 31, 2022
Blog Article
Decibio Analytics launches inaugural NGS Oncology DxBook
Discover the new DxBook for clinical NGS oncology testing.
August 31, 2022
Blog Article
Multiplex Tissue Analysis & Digital Pathology Trial Analysis
The accumulation of biomarker-matched clinical outcome data may imply that a new diagnostic is poised to approach the clinic.
August 31, 2022
Blog Article
Multiplex Tissue Analysis & Digital Pathology Trial Analysis
The accumulation of biomarker-matched clinical outcome data may imply that a new diagnostic is poised to approach the clinic.
August 31, 2022
DeciBio Q&A
The Promise of Clinical Digital Pathology: DeciBio's Q&A with Mark Lloyd of Inspirata
Read as our experts interview Mark Lloyd, Executive Vice President and Founder of Inspirata, about the promise of Clinical Digital Pathology.
August 30, 2022
DeciBio Q&A
The Promise of Clinical Digital Pathology: DeciBio's Q&A with Mark Lloyd of Inspirata
Read as our experts interview Mark Lloyd, Executive Vice President and Founder of Inspirata, about the promise of Clinical Digital Pathology.
August 30, 2022
Blog Article
The Partnerships Setting the Stage for the Digital Pathology Revolution
Our experts took a look at digital pathology partnerships more broadly, to identify the companies and collaborations that are enabling more widespread access to digital pathology tools.
August 24, 2022
Blog Article
The Partnerships Setting the Stage for the Digital Pathology Revolution
Our experts took a look at digital pathology partnerships more broadly, to identify the companies and collaborations that are enabling more widespread access to digital pathology tools.
August 24, 2022
In The Press
The Top 50 Healthcare Leaders in Consulting of 2022
Partners, Andrew Aijian and Stephane Budel, place in The Consulting Report's, "The Top 50 Healthcare Leaders in Consulting of 2022".
August 24, 2022
In The Press
The Top 50 Healthcare Leaders in Consulting of 2022
Partners, Andrew Aijian and Stephane Budel, place in The Consulting Report's, "The Top 50 Healthcare Leaders in Consulting of 2022".
August 24, 2022
Blog Article
DxBooks Data Insights: Two Types of Infectious Disease Market Growth
Our clinical diagnostics market research highlights two analyte-level trends in the infectious diseases testing market.
August 22, 2022
Blog Article
DxBooks Data Insights: Two Types of Infectious Disease Market Growth
Our clinical diagnostics market research highlights two analyte-level trends in the infectious diseases testing market.
August 22, 2022
In The Press
LABJ - Best Places to Work Awards
DeciBio Consulting joined the rankings of the TOP 100 companies in Los Angeles that are setting trends and redefining the employee experience.
August 18, 2022
In The Press
LABJ - Best Places to Work Awards
DeciBio Consulting joined the rankings of the TOP 100 companies in Los Angeles that are setting trends and redefining the employee experience.
August 18, 2022
DeciBio Culture
DeciBio Profile: Life Science Expert
This is a profile of what it is like to be a life science expert at DeciBio consulting. Check it out to learn more about having a PhD and becoming a consultant.
August 9, 2022
DeciBio Culture
DeciBio Profile: Life Science Expert
This is a profile of what it is like to be a life science expert at DeciBio consulting. Check it out to learn more about having a PhD and becoming a consultant.
August 9, 2022
In The Press
The Methylation Analysis Landscape In 2022
Read about the current Methylation Analysis Landscape projection for the year 2022 in our newest publication.
August 8, 2022
In The Press
The Methylation Analysis Landscape In 2022
Read about the current Methylation Analysis Landscape projection for the year 2022 in our newest publication.
August 8, 2022
Newsletter Update
Liquid Biopsy | July Roundup
July showcased new partnerships, product launches, clinical trials, and study result updates in liquid biopsy.
August 8, 2022
Newsletter Update
Liquid Biopsy | July Roundup
July showcased new partnerships, product launches, clinical trials, and study result updates in liquid biopsy.
August 8, 2022
In The Press
Your 3-Step Process For Innovation In Precision Medicine
Read about how understanding the market, distinct value proposition, business model, and clinical actionability of a product is essential to bridging the gap between early-stage ideas and commercialized successes.
August 4, 2022
In The Press
Your 3-Step Process For Innovation In Precision Medicine
Read about how understanding the market, distinct value proposition, business model, and clinical actionability of a product is essential to bridging the gap between early-stage ideas and commercialized successes.
August 4, 2022
DeciBio Q&A
Series A Success: DeciBio’s Q&A with Trey Foskett of Watchmaker Genomics
DeciBio interviews Trey Foskett, Co-Founder and CEO of Watchmaker Genomics.
August 2, 2022
DeciBio Q&A
Series A Success: DeciBio’s Q&A with Trey Foskett of Watchmaker Genomics
DeciBio interviews Trey Foskett, Co-Founder and CEO of Watchmaker Genomics.
August 2, 2022
In The Press
DeciBio Ventures invests in $55m Replay seed funding round led by KKR & Co and OMX Ventures
Check out our latest feature on PE insider about recent news regarding DeciBio Ventures.
August 2, 2022
In The Press
DeciBio Ventures invests in $55m Replay seed funding round led by KKR & Co and OMX Ventures
Check out our latest feature on PE insider about recent news regarding DeciBio Ventures.
August 2, 2022
Blog Article
ctDNA MRD and Monitoring Front and Center at ASCO 2022
ctDNA MRD and monitoring was front and center at ASCO 2022. We analyzed 19 abstracts published by leading commercial players.
August 2, 2022
Blog Article
ctDNA MRD and Monitoring Front and Center at ASCO 2022
ctDNA MRD and monitoring was front and center at ASCO 2022. We analyzed 19 abstracts published by leading commercial players.
August 2, 2022
Newsletter Update
Next-Generation Therapeutics | July Roundup
July stands out for its wealth of news on company growth - read about some of the many financing rounds, acquisitions, and partnerships the next-gen space saw in the last month.
July 29, 2022
Newsletter Update
Next-Generation Therapeutics | July Roundup
July stands out for its wealth of news on company growth - read about some of the many financing rounds, acquisitions, and partnerships the next-gen space saw in the last month.
July 29, 2022
DeciBio Q&A
mIF Landscape and COMET Launch: DeciBio’s Q&A with Déborah Heintze of Lunaphore
Our Q&A with co-founder and CMO at Lunaphore, Déborah Heintze, dives into the spatial biology market today and covers key details on Lunaphore’s new COMET platform.
July 27, 2022
DeciBio Q&A
mIF Landscape and COMET Launch: DeciBio’s Q&A with Déborah Heintze of Lunaphore
Our Q&A with co-founder and CMO at Lunaphore, Déborah Heintze, dives into the spatial biology market today and covers key details on Lunaphore’s new COMET platform.
July 27, 2022
DeciBio News
DeciBio Ventures Invests in Replay’s $55M seed funding round led by KKR & Co. and OMX Ventures
DeciBio Ventures invested in the seed funding round for Replay. KKR & Co. Inc. and OMX Ventures led this funding round, which totaled $55 million.
July 25, 2022
DeciBio News
DeciBio Ventures Invests in Replay’s $55M seed funding round led by KKR & Co. and OMX Ventures
DeciBio Ventures invested in the seed funding round for Replay. KKR & Co. Inc. and OMX Ventures led this funding round, which totaled $55 million.
July 25, 2022
Blog Article
Introduction to MtDNA: A Burgeoning Biomarker in Cancer
With the rapid growth of liquid biopsy research, biomarkers like mtDNA, in addition to more “traditional” analytes (e.g., ctDNA, cfDNA, proteins), are being pursued.
July 15, 2022
Blog Article
Introduction to MtDNA: A Burgeoning Biomarker in Cancer
With the rapid growth of liquid biopsy research, biomarkers like mtDNA, in addition to more “traditional” analytes (e.g., ctDNA, cfDNA, proteins), are being pursued.
July 15, 2022
Newsletter Update
Liquid Biopsy | June Roundup
Liquid Biopsy (LBx) in June was spearheaded by novel company partnerships and product launches as well as clinical trial launches and validation study result updates.
July 11, 2022
Newsletter Update
Liquid Biopsy | June Roundup
Liquid Biopsy (LBx) in June was spearheaded by novel company partnerships and product launches as well as clinical trial launches and validation study result updates.
July 11, 2022
Newsletter Update
Next-Generation Therapeutics Newsletter | June Roundup
June was a busy month with funding rounds, study results, and manufacturing partnerships bringing a range of next gen therapeutics closer to the clinic. Happy reading!
July 1, 2022
Newsletter Update
Next-Generation Therapeutics Newsletter | June Roundup
June was a busy month with funding rounds, study results, and manufacturing partnerships bringing a range of next gen therapeutics closer to the clinic. Happy reading!
July 1, 2022
Newsletter Update
Digital Health | Q2 Update
We’ve rounded up the big headlines for you, from an Office of Inspector General data brief to exciting regulatory approvals, product launches, partnerships, and acquisitions in the digital health space.
July 1, 2022
Newsletter Update
Digital Health | Q2 Update
We’ve rounded up the big headlines for you, from an Office of Inspector General data brief to exciting regulatory approvals, product launches, partnerships, and acquisitions in the digital health space.
July 1, 2022
Blog Article
Multiomics takes centerstage at PMWC 2022
Our life science expert highlights a key insight from this year's Precision World Medicine Conference. From digital biomarkers to liquid biopsy, read how multiomics is becoming a central part of precision medicine
July 1, 2022
Blog Article
Multiomics takes centerstage at PMWC 2022
Our life science expert highlights a key insight from this year's Precision World Medicine Conference. From digital biomarkers to liquid biopsy, read how multiomics is becoming a central part of precision medicine
July 1, 2022
DeciBio Q&A
The Next Frontier of Sensitivity: DeciBio’s Q&A with Stephane Mouradian of Personalis
DeciBio interviews Stephane Mouradian, Senior Vice President of BD & Marketing at Personalis, about the focus of the company moving forward and their highly sensitive NeXT Personal™ assay.
June 24, 2022
DeciBio Q&A
The Next Frontier of Sensitivity: DeciBio’s Q&A with Stephane Mouradian of Personalis
DeciBio interviews Stephane Mouradian, Senior Vice President of BD & Marketing at Personalis, about the focus of the company moving forward and their highly sensitive NeXT Personal™ assay.
June 24, 2022
DeciBio Q&A
DeciBio’s Peripheral Biomarkers Q&A with Dr. Ofer Sharon of OncoHost
In this Q&A, our experts interviewed Ofer Sharon, MD, MBA, is CEO and co-founder of OncoHost, a host response profiling company in the peripheral biomarkers space.
June 23, 2022
DeciBio Q&A
DeciBio’s Peripheral Biomarkers Q&A with Dr. Ofer Sharon of OncoHost
In this Q&A, our experts interviewed Ofer Sharon, MD, MBA, is CEO and co-founder of OncoHost, a host response profiling company in the peripheral biomarkers space.
June 23, 2022
In The Press
Pharma Manufacturing - mRNA boom: A double-edged sword
Did short-term solutions for COVID-19 stifle long-term mRNA success?
June 23, 2022
In The Press
Pharma Manufacturing - mRNA boom: A double-edged sword
Did short-term solutions for COVID-19 stifle long-term mRNA success?
June 23, 2022
DeciBio Q&A
Next-Generation Programmable mRNA Therapies Post COVID-19 with Jacob Becraft of Strand Therapeutics
New Podcast Episode: DeciBio interviews Jacob Becraft, the CEO and co-founder of Strand Therapeutics.
June 22, 2022
DeciBio Q&A
Next-Generation Programmable mRNA Therapies Post COVID-19 with Jacob Becraft of Strand Therapeutics
New Podcast Episode: DeciBio interviews Jacob Becraft, the CEO and co-founder of Strand Therapeutics.
June 22, 2022
Infographic
The Precision Oncology Landscape Infographic [Updated June 2022]
The precision oncology landscape is getting crowded, with an increasing number of players offering solutions throughout the diagnostic and treatment journey.
June 14, 2022
Infographic
The Precision Oncology Landscape Infographic [Updated June 2022]
The precision oncology landscape is getting crowded, with an increasing number of players offering solutions throughout the diagnostic and treatment journey.
June 14, 2022
DeciBio Q&A
Cell Therapy Trends: ArsenalBio's differentiation strategy and long-term plans with Tarjei Mikkelsen
We had the chance to talk with Tarjei Mikkelsen PhD, CTO at ArsenalBio, a programmable cell therapy company, to get his thoughts on the cell therapy field.
June 13, 2022
DeciBio Q&A
Cell Therapy Trends: ArsenalBio's differentiation strategy and long-term plans with Tarjei Mikkelsen
We had the chance to talk with Tarjei Mikkelsen PhD, CTO at ArsenalBio, a programmable cell therapy company, to get his thoughts on the cell therapy field.
June 13, 2022
Blog Article
AGBT 2022: DeciBio Highlights – Back to Technological Innovation
The level of new announcements and innovation was one of the most impressive in recent memory and appeared non-linear compared to previous years.
June 10, 2022
Blog Article
AGBT 2022: DeciBio Highlights – Back to Technological Innovation
The level of new announcements and innovation was one of the most impressive in recent memory and appeared non-linear compared to previous years.
June 10, 2022
Newsletter Update
Next-Generation Therapeutics Newsletter | May Roundup
This month we have seen major new trial developments and partnership changes in the cell therapy space, creative funding rounds across gene therapies, and significant manufacturing expansions for oligonucleotide therapies.
June 8, 2022
Newsletter Update
Next-Generation Therapeutics Newsletter | May Roundup
This month we have seen major new trial developments and partnership changes in the cell therapy space, creative funding rounds across gene therapies, and significant manufacturing expansions for oligonucleotide therapies.
June 8, 2022
Newsletter Update
Liquid Biopsy | May Roundup
Liquid Biopsy (LBx) continued to develop through May, featuring new CE-IVD and FDA approvals, research and commercialization collaborations, and new trial launches and study results.
June 1, 2022
Newsletter Update
Liquid Biopsy | May Roundup
Liquid Biopsy (LBx) continued to develop through May, featuring new CE-IVD and FDA approvals, research and commercialization collaborations, and new trial launches and study results.
June 1, 2022
Newsletter Update
Liquid Biopsy | April Roundup
Liquid Biopsy (LBx) continued to develop through April, featuring new clinical and research collaborations as well as trial launches and study results.
May 11, 2022
Newsletter Update
Liquid Biopsy | April Roundup
Liquid Biopsy (LBx) continued to develop through April, featuring new clinical and research collaborations as well as trial launches and study results.
May 11, 2022
DeciBio Q&A
Cancer Detection in Dogs: OncoK9 Liquid Biopsy and the CANDiD Study Q&A with Daniel Grosu of PetDx
A few of our experts talk with Daniel S. Grosu, MD, MBA, Founder, President and CEO of PetDx, a liquid biopsy company that intends to revolutionize how we detect cancer in man’s best friend — canines.
May 3, 2022
DeciBio Q&A
Cancer Detection in Dogs: OncoK9 Liquid Biopsy and the CANDiD Study Q&A with Daniel Grosu of PetDx
A few of our experts talk with Daniel S. Grosu, MD, MBA, Founder, President and CEO of PetDx, a liquid biopsy company that intends to revolutionize how we detect cancer in man’s best friend — canines.
May 3, 2022
Blog Article
Multiplex Tissue Analysis and Digital Pathology - A summary of AACR 2022 Findings
Our biomarker intelligence team summarizes critical insights on multiplex tissue analysis and digital pathology from AACR 2022. Discover key activity and key players involved in the latest clinical research.
April 21, 2022
Blog Article
Multiplex Tissue Analysis and Digital Pathology - A summary of AACR 2022 Findings
Our biomarker intelligence team summarizes critical insights on multiplex tissue analysis and digital pathology from AACR 2022. Discover key activity and key players involved in the latest clinical research.
April 21, 2022
DeciBio Q&A
The Future of Proteomics: Seer’s Origins & the Proteograph’s Commercial Launch Q&A with Omid Farokhzad
We interviewed Omid Farokhzad about the Future of Proteomics: Seer’s Origins & the Proteograph’s Commercial Launch.
April 20, 2022
DeciBio Q&A
The Future of Proteomics: Seer’s Origins & the Proteograph’s Commercial Launch Q&A with Omid Farokhzad
We interviewed Omid Farokhzad about the Future of Proteomics: Seer’s Origins & the Proteograph’s Commercial Launch.
April 20, 2022
Newsletter Update
Digital Health | Q1 2022 Update
From ViVE 2022 to exciting regulatory approvals, product launches, partnerships, and acquisitions for the digital health space, Q1 2022 is off to an eventful start.
April 5, 2022
Newsletter Update
Digital Health | Q1 2022 Update
From ViVE 2022 to exciting regulatory approvals, product launches, partnerships, and acquisitions for the digital health space, Q1 2022 is off to an eventful start.
April 5, 2022
Newsletter Update
Liquid Biopsy | March Roundup
Liquid Biopsy (LBx) continues to develop with each month, featuring more clinical trial updates and platform launches as well as new LBx approvals worldwide.
April 4, 2022
Newsletter Update
Liquid Biopsy | March Roundup
Liquid Biopsy (LBx) continues to develop with each month, featuring more clinical trial updates and platform launches as well as new LBx approvals worldwide.
April 4, 2022
DeciBio Q&A
DeciBio’s Single Cell Q&A with Sean Mackay of IsoPlexis
The field of single cell continues to evolve at a remarkable pace. We caught up with CEO and co-founder Sean Mackay to hear more about recent developments at the company.
March 29, 2022
DeciBio Q&A
DeciBio’s Single Cell Q&A with Sean Mackay of IsoPlexis
The field of single cell continues to evolve at a remarkable pace. We caught up with CEO and co-founder Sean Mackay to hear more about recent developments at the company.
March 29, 2022
DeciBio Q&A
DeciBio's Spatial Omics Q&A with Michael Schnall-Levin of 10x Genomics
Our research tools consulting experts discuss the exciting spatial omics market with Michael Schnall-Levin, specifically how novel technologies are enabling high-plex spatial imaging for translational and discovery research.
March 15, 2022
DeciBio Q&A
DeciBio's Spatial Omics Q&A with Michael Schnall-Levin of 10x Genomics
Our research tools consulting experts discuss the exciting spatial omics market with Michael Schnall-Levin, specifically how novel technologies are enabling high-plex spatial imaging for translational and discovery research.
March 15, 2022
DeciBio Q&A
DeciBio's Spatial Omics Q&A with Niro Ramachandran of Akoya Biosciences
Our research tools consulting experts discuss the exciting spatial omics market with Niro Ramachandran.
March 9, 2022
DeciBio Q&A
DeciBio's Spatial Omics Q&A with Niro Ramachandran of Akoya Biosciences
Our research tools consulting experts discuss the exciting spatial omics market with Niro Ramachandran.
March 9, 2022
Newsletter Update
Liquid Biopsy | February Roundup
Liquid Biopsy (LBx) continues to be of relevance now and in the future, with more clinical trial updates and launches taking place every month, as well as with new LBx approvals worldwide.
March 3, 2022
Newsletter Update
Liquid Biopsy | February Roundup
Liquid Biopsy (LBx) continues to be of relevance now and in the future, with more clinical trial updates and launches taking place every month, as well as with new LBx approvals worldwide.
March 3, 2022
DeciBio News
DeciBio Consulting Advances in the Vault Consulting 50
DeciBio Consulting was again named a top consulting firm to work for in North America. Vault.com awarded DeciBio the #30 ranking on its 2022 edition of its signature list, the Vault Consulting 50. DeciBio also advanced to #4 on Vault’s 2022 Best Boutique Consulting Firms list. DeciBio is one of the youngest firms on either list.
February 15, 2022
DeciBio News
DeciBio Consulting Advances in the Vault Consulting 50
DeciBio Consulting was again named a top consulting firm to work for in North America. Vault.com awarded DeciBio the #30 ranking on its 2022 edition of its signature list, the Vault Consulting 50. DeciBio also advanced to #4 on Vault’s 2022 Best Boutique Consulting Firms list. DeciBio is one of the youngest firms on either list.
February 15, 2022
Newsletter Update
Liquid Biopsy | January Roundup
Liquid Biopsy (LBx) companies push forward on clinical trial inclusion for greater real world validation, cancer indication expansion for existing assays, and regulatory approval in the US and Europe.
February 7, 2022
Newsletter Update
Liquid Biopsy | January Roundup
Liquid Biopsy (LBx) companies push forward on clinical trial inclusion for greater real world validation, cancer indication expansion for existing assays, and regulatory approval in the US and Europe.
February 7, 2022
DeciBio News
Spatial Omics Landscape Analysis in Collaboration with the Center for Integrated Diagnostics
Our research tools consulting experts discuss the clinical transition of spatial omics technologies.
January 18, 2022
DeciBio News
Spatial Omics Landscape Analysis in Collaboration with the Center for Integrated Diagnostics
Our research tools consulting experts discuss the clinical transition of spatial omics technologies.
January 18, 2022
Newsletter Update
Digital Health | Q4 Update
Q4 2021 was an exciting quarter for #digitalhealth with a focus on new product launches, new players, acquisitions, and regulatory updates.
January 12, 2022
Newsletter Update
Digital Health | Q4 Update
Q4 2021 was an exciting quarter for #digitalhealth with a focus on new product launches, new players, acquisitions, and regulatory updates.
January 12, 2022
Newsletter Update
Liquid Biopsy | End of the Year Roundup
End-of-the-year 2021 poised the Liquid Biopsy industry to have an explosive new year in 2022 with multiple medicare coverage designations, product launches, clinical trial progression, and promising funding rounds.
January 10, 2022
Newsletter Update
Liquid Biopsy | End of the Year Roundup
End-of-the-year 2021 poised the Liquid Biopsy industry to have an explosive new year in 2022 with multiple medicare coverage designations, product launches, clinical trial progression, and promising funding rounds.
January 10, 2022
DeciBio News
DeciBio Consulting adds Miguel Edwards, Ph.D., as a Partner and Head of its Bay Area Office
DeciBio Consulting, LLC, has tapped Miguel Edwards, Ph.D., as Partner.
January 10, 2022
DeciBio News
DeciBio Consulting adds Miguel Edwards, Ph.D., as a Partner and Head of its Bay Area Office
DeciBio Consulting, LLC, has tapped Miguel Edwards, Ph.D., as Partner.
January 10, 2022
DeciBio Culture
Why DeciBio?
Discover the top three differentiators that set DeciBio consulting apart from other consulting firms
January 5, 2022
DeciBio Culture
Why DeciBio?
Discover the top three differentiators that set DeciBio consulting apart from other consulting firms
January 5, 2022
Blog Article
2022 Cell and Gene Therapy Field Predictions
With record investment going into next-generation therapies, we take stock of the field and make our predictions for what 2022 will bring for gene and cell therapies.
January 3, 2022
Blog Article
2022 Cell and Gene Therapy Field Predictions
With record investment going into next-generation therapies, we take stock of the field and make our predictions for what 2022 will bring for gene and cell therapies.
January 3, 2022
DeciBio News
DeciBio Consulting Announces Debut Venture Fund, DeciBio Ventures, to Support Ground-Breaking Precision Medicine Companies
DeciBio Ventures aims to invest in start-ups across both tools and therapeutics
December 15, 2021
DeciBio News
DeciBio Consulting Announces Debut Venture Fund, DeciBio Ventures, to Support Ground-Breaking Precision Medicine Companies
DeciBio Ventures aims to invest in start-ups across both tools and therapeutics
December 15, 2021
Blog Article
Spherical Nucleic Acids: How geometry can revolutionize nucleic acid delivery
This article discusses how Spherical Nucleic Acids are differentiated and the current commercial pipeline.
December 13, 2021
Blog Article
Spherical Nucleic Acids: How geometry can revolutionize nucleic acid delivery
This article discusses how Spherical Nucleic Acids are differentiated and the current commercial pipeline.
December 13, 2021
Newsletter Update
Liquid Biopsy | November Roundup
November 2021 was packed full of promising developments across the Liquid Biopsy (LBx) industry with major regulatory developments, clinical trials announcements, new product launches and performance updates, and much more.
December 7, 2021
Newsletter Update
Liquid Biopsy | November Roundup
November 2021 was packed full of promising developments across the Liquid Biopsy (LBx) industry with major regulatory developments, clinical trials announcements, new product launches and performance updates, and much more.
December 7, 2021
Blog Article
Multiplex Tissue Analysis – A Summary of SITC 2021 Findings
This review highlights meta-analysis of all MTA abstracts identified at the SITC 2021 annual meeting.
December 2, 2021
Blog Article
Multiplex Tissue Analysis – A Summary of SITC 2021 Findings
This review highlights meta-analysis of all MTA abstracts identified at the SITC 2021 annual meeting.
December 2, 2021
DeciBio Q&A
Investing in People-Centric Healthcare with Jessica Owens
We speak with Jessica Owens about what makes for a successful life science venture, how digital biomarkers start to play into the precision medicine landscape, and more.
November 8, 2021
DeciBio Q&A
Investing in People-Centric Healthcare with Jessica Owens
We speak with Jessica Owens about what makes for a successful life science venture, how digital biomarkers start to play into the precision medicine landscape, and more.
November 8, 2021
DeciBio Culture
DeciBio's Company Culture
DeciBio Consulting upholds a strong company culture and encourages a healthy work life balance. This video highlights what it is like to be a "DeciBion".
November 5, 2021
DeciBio Culture
DeciBio's Company Culture
DeciBio Consulting upholds a strong company culture and encourages a healthy work life balance. This video highlights what it is like to be a "DeciBion".
November 5, 2021
Newsletter Update
Liquid Biopsy Fall 2021 Update
September and October 2021 were packed full of promising developments across the Liquid Biopsy (LBx) industry with new product launches, clinical trials, regulatory developments, and much more.
November 4, 2021
Newsletter Update
Liquid Biopsy Fall 2021 Update
September and October 2021 were packed full of promising developments across the Liquid Biopsy (LBx) industry with new product launches, clinical trials, regulatory developments, and much more.
November 4, 2021
DeciBio News
DeciBio Consulting goes carbon neutral
DeciBio Consulting, the leading precision medicine strategy consulting firm, will become carbon neutral in 2022. To help accomplish this carbon neutral goal, DeciBio is partnering with My Forest Armenia (MFA), a nonprofit organization that plants trees and funds scientific research.
November 2, 2021
DeciBio News
DeciBio Consulting goes carbon neutral
DeciBio Consulting, the leading precision medicine strategy consulting firm, will become carbon neutral in 2022. To help accomplish this carbon neutral goal, DeciBio is partnering with My Forest Armenia (MFA), a nonprofit organization that plants trees and funds scientific research.
November 2, 2021
DeciBio Q&A
DeciBio’s Single Cell Multiomic Q&A with Anjali Pradhan of Mission Bio
We caught up with Anjali Pradhan, the Vice President of Product Management at Mission Bio to hear more about recent developments at the company.
October 18, 2021
DeciBio Q&A
DeciBio’s Single Cell Multiomic Q&A with Anjali Pradhan of Mission Bio
We caught up with Anjali Pradhan, the Vice President of Product Management at Mission Bio to hear more about recent developments at the company.
October 18, 2021
DeciBio Q&A
DeciBio's Spatial Omics Q&A with Garry Nolan of Stanford University
Our research tools consulting experts discuss the exciting spatial omics market with Garry Nolan.
September 15, 2021
DeciBio Q&A
DeciBio's Spatial Omics Q&A with Garry Nolan of Stanford University
Our research tools consulting experts discuss the exciting spatial omics market with Garry Nolan.
September 15, 2021
DeciBio Culture
The DeciBio Difference
Learn about what distinguishes DeciBio from various members at the firm.
August 27, 2021
DeciBio Culture
The DeciBio Difference
Learn about what distinguishes DeciBio from various members at the firm.
August 27, 2021
Blog Article
The race is on: Competition in cancer early detection intensifies
Oncology has driven the adoption of precision medicine, which in turn has resulted in dramatic improvements for patient outcomes in some indications.
August 3, 2021
Blog Article
The race is on: Competition in cancer early detection intensifies
Oncology has driven the adoption of precision medicine, which in turn has resulted in dramatic improvements for patient outcomes in some indications.
August 3, 2021
Blog Article
Precision medicine poised to disrupt fertility care paradigm
While R&D efforts to date have made significant strides in improving diagnostic and therapeutic options for infertility, there is still a massive unmet need to personalize diagnosis and treatment options.
July 20, 2021
Blog Article
Precision medicine poised to disrupt fertility care paradigm
While R&D efforts to date have made significant strides in improving diagnostic and therapeutic options for infertility, there is still a massive unmet need to personalize diagnosis and treatment options.
July 20, 2021
Blog Article
Industry Snapshot: The nascent ctDNA MRD space continues to see rapid growth
2020 and 2021 have proven to be incredibly exciting and pivotal times for ctDNA MRD and monitoring: multiple companies noted intentions to enter the MRD / monitoring space
June 29, 2021
Blog Article
Industry Snapshot: The nascent ctDNA MRD space continues to see rapid growth
2020 and 2021 have proven to be incredibly exciting and pivotal times for ctDNA MRD and monitoring: multiple companies noted intentions to enter the MRD / monitoring space
June 29, 2021
DeciBio Q&A
DeciBio’s Spatial Omics Q&A with Brian McKelligon of Akoya Biosciences
Akoya Biosciences has emerged as a key player in the spatial biology market, and we had the opportunity to speak with their CEO - Brian McKelligon.
June 29, 2021
DeciBio Q&A
DeciBio’s Spatial Omics Q&A with Brian McKelligon of Akoya Biosciences
Akoya Biosciences has emerged as a key player in the spatial biology market, and we had the opportunity to speak with their CEO - Brian McKelligon.
June 29, 2021
DeciBio Q&A
Q&A with Suchismita Acharya – Founder and CEO of AyuVis Research
We had the opportunity to speak with Suchismita Acharya about her experiences starting AyuVis Research. AyuVis Research is a preclinical stage pharmaceutical company in Fort Worth, TX
June 29, 2021
DeciBio Q&A
Q&A with Suchismita Acharya – Founder and CEO of AyuVis Research
We had the opportunity to speak with Suchismita Acharya about her experiences starting AyuVis Research. AyuVis Research is a preclinical stage pharmaceutical company in Fort Worth, TX
June 29, 2021
DeciBio Q&A
Q&A with Stephanie Campbell – Co-Founder of the Artemis Fund
We had the opportunity to speak with Stephanie Campbell about her experiences as a co-founder of The Artemis Fund
June 21, 2021
DeciBio Q&A
Q&A with Stephanie Campbell – Co-Founder of the Artemis Fund
We had the opportunity to speak with Stephanie Campbell about her experiences as a co-founder of The Artemis Fund
June 21, 2021
Blog Article
Multiplex Tissue Analysis + Digital Pathology in Clinical Research – A Summary of ASCO 2021 Findings
The range of technologies that enable multiplex tissue analysis (MTA) and digital pathology (DigPath) are rapidly growing and entering the clinical research space.
June 16, 2021
Blog Article
Multiplex Tissue Analysis + Digital Pathology in Clinical Research – A Summary of ASCO 2021 Findings
The range of technologies that enable multiplex tissue analysis (MTA) and digital pathology (DigPath) are rapidly growing and entering the clinical research space.
June 16, 2021
Blog Article
COVID’s Effect on mRNA Assets, Part II: Experience (and Quality) Matters
With renewed interest in disparate applications and the subsequent flood of newcomers to mRNA asset development, the focus on quality and experience with regard to mRNA is more important than ever.
June 2, 2021
Blog Article
COVID’s Effect on mRNA Assets, Part II: Experience (and Quality) Matters
With renewed interest in disparate applications and the subsequent flood of newcomers to mRNA asset development, the focus on quality and experience with regard to mRNA is more important than ever.
June 2, 2021
DeciBio Q&A
Q&A with Michelle Dipp – Co-Founder and Managing Partner at Biospring Partners
We had the opportunity to speak with Michelle Dipp about her experiences as a co-founder of Biospring Partners
June 1, 2021
DeciBio Q&A
Q&A with Michelle Dipp – Co-Founder and Managing Partner at Biospring Partners
We had the opportunity to speak with Michelle Dipp about her experiences as a co-founder of Biospring Partners
June 1, 2021
DeciBio Q&A
The Galaxy's Guardians with Dr. Chris Mason
We’ll talk about how he envisions humanity preparing to move beyond our home on earth in the next few centuries, and how that relates to precision medicine over the next few years.
May 27, 2021
DeciBio Q&A
The Galaxy's Guardians with Dr. Chris Mason
We’ll talk about how he envisions humanity preparing to move beyond our home on earth in the next few centuries, and how that relates to precision medicine over the next few years.
May 27, 2021
In The Press
How Inclusion In Precision Medicine Could Drive Market Success And Minimize Disparities
Partner Stephane Budel believes precision medicine has the potential to drastically improve health care outcomes
May 26, 2021
In The Press
How Inclusion In Precision Medicine Could Drive Market Success And Minimize Disparities
Partner Stephane Budel believes precision medicine has the potential to drastically improve health care outcomes
May 26, 2021
Blog Article
Navigating Companion Diagnostics (CDx) – Multiple Stakeholders, Many Goals
Companion diagnostic (CDx) tests are a foundational tool in precision medicine, helping ensure only the right patients receive the right therapies.
May 25, 2021
Blog Article
Navigating Companion Diagnostics (CDx) – Multiple Stakeholders, Many Goals
Companion diagnostic (CDx) tests are a foundational tool in precision medicine, helping ensure only the right patients receive the right therapies.
May 25, 2021
Blog Article
Lessons in Digital Health Platform Acquisition from IBM’s Watson
After nearly a decade of disappointment after disappointment, IBM announced earlier this year that they are looking to sell Watson Health.
May 17, 2021
Blog Article
Lessons in Digital Health Platform Acquisition from IBM’s Watson
After nearly a decade of disappointment after disappointment, IBM announced earlier this year that they are looking to sell Watson Health.
May 17, 2021
DeciBio Q&A
DeciBio's Spatial Omics Q&A with Terry Lo and George Emanuel of Vizgen
We had the opportunity to speak with Terry Lo and George Emanuel to discuss the announcement, MERSCOPE, and the spatial omics industry overall
May 13, 2021
DeciBio Q&A
DeciBio's Spatial Omics Q&A with Terry Lo and George Emanuel of Vizgen
We had the opportunity to speak with Terry Lo and George Emanuel to discuss the announcement, MERSCOPE, and the spatial omics industry overall
May 13, 2021
DeciBio Q&A
DeciBio’s Q&A with Omead Ostadan — President & COO of Seer, Inc.
We had the opportunity to sit down and discuss Seer’s technology and the proteomics market with Omead Ostadan
May 7, 2021
DeciBio Q&A
DeciBio’s Q&A with Omead Ostadan — President & COO of Seer, Inc.
We had the opportunity to sit down and discuss Seer’s technology and the proteomics market with Omead Ostadan
May 7, 2021

Precision Medicine is evolving at a rapid pace

Discover how we can help

Contact Us
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.